Figure 2

EGFR inhibitor attenuated anti-tumor responses of EGFR _875–889 -reactive CD4 ⁺ T cell clones against Sa-3. (A) (B) EGFR_875–889-reactive CD4⁺ T cell clones T8 (DR53-restricted) and M8 (DR53-restricted) were tested for their capacity to recognize antigen directly on EGFR-positive, HLA-DR matched HNSCC cell line HSC-4 or Sa-3 by IFN-γ production. Tumor cells were pretreated 48 h with or without erlotinib (1 μM). DMSO was used as negative control. Columns without bars had SD of <10% of mean values. Results are representative of three separate experiments. *p < 0.05.